Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)

Abstract

Breast cancer represents a major threat to women's health in China. Its continuously rising incidence contributes to a growing disease burden, thereby creating a critical demand for novel and effective therapeutic strategies. In recent years, poly ADP-ribose polymerase (PARP) inhibitors, as a novel class of anti-tumor drugs targeting the DNA damage repair pathway, have demonstrated remarkable efficacy in treating breast cancer with BRCA1/2 mutations. By selectively inhibiting DNA repair in tumor cells, these agents induce a “synthetic lethality” effect, offering a new option for precision therapy. Currently, PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use. This consensus, based on the latest evidence-based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice.